FDA approves trastuzumab biosimilar for breast, stomach cancers

Access to the full content of this site is available only to registered healthcare professionals. Register to read more


  • The US Food and Drug Administration (FDA) has approved trastuzumab-dkst as a biosimilar to trastuzumab for the treatment of HER2-overexpressing breast or metastatic gastric or gastroesophageal junction adenocarcinoma.

Why this matters

  • Trastuzumab-dkst is just the second bi...